The recent federal spending bill includes a provision that allows Medicare to cover multi‑cancer early detection (MCED) tests following FDA approval, sidestepping the traditionally lengthy USPSTF pathway. Coverage would begin in 2029 with reimbursement tied to existing stool‑DNA test rates and phased eligibility for beneficiary ages. The move directly addresses a long‑standing industry priority and removes a major barrier to commercial scale for MCED developers. Companies such as Exact Sciences publicly welcomed the provision, which could expand access and accelerate adoption of blood‑based screening once tests clear the FDA. The change is likely to reshape payer negotiations, clinical implementation timelines and investment calculus in the diagnostics sector.